Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting

Irina V. Balyasnikova*, Julia V. Berestetskaya, David J. Visintine, Andrew B. Nesterovitch, Larisa Adamian, Sergei M. Danilov

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Monoclonal antibody (mAb) 9B9 to angiotensin-converting enzyme (ACE) demonstrates selective accumulation in lung tissue of the rat, hamster, cat, monkey and human after systemic injection. It has also been demonstrated that mAb 9B9 is the useful tool for targeting therapeutic agents or genes to lung endothelium. In this study, we describe the generation and characterization of a single-chain derivative (scFv) of mAb9B9 (scFv 9B9). In vitro, scFv9B9 retains the ability of the parental antibody to recognize human and rat ACE when expressed both on the surface of phage and as a soluble protein in prokaryotic and eukaryotic expression systems. The ability of scFv 9B9 presented by phage or the soluble protein labeled with I125 to recognize ACE in the pulmonary circulation was also confirmed in an in vivo rat model. Sequence analysis revealed a putative glycosylation site in close proximity to the complementarity determining region 2 (CDR2) of the scFv 9B9 heavy chain. Mutation of Asn68 to Gln in the heavy chain of scFv 9B9 eliminated the glycosylation site and significantly improved the binding affinity of scFv 9B9 to human ACE as determined by cell ELISA and Western Blot. Moreover, Asn68Gln scFv 9B9 showed a greater rate of secretion at 30°C than wild type scFv 9B9, but had a decreased thermal stability at 37°C. The development of a stable and functional single-chain format of mAb 9B9 which specifically recognizes human and rat ACE represents a novel antibody-based reagent suitable for targeted delivery of drugs/genes to the pulmonary circulation.

Original languageEnglish (US)
Pages (from-to)355-364
Number of pages10
JournalMicrovascular Research
Volume80
Issue number3
DOIs
StatePublished - Dec 1 2010

Fingerprint

Cloning
Peptidyl-Dipeptidase A
Organism Cloning
Monoclonal Antibodies
Rats
Lung
Glycosylation
Bacteriophages
Pulmonary Circulation
Genes
Complementarity Determining Regions
Antibodies
Cricetinae
Endothelium
Haplorhini
Sequence Analysis
Proteins
Cats
Thermodynamic stability
Hot Temperature

Keywords

  • Angiotensin-converting enzyme
  • Pulmonary endothelium
  • Single-chain antibody fragment
  • Targeting

ASJC Scopus subject areas

  • Biochemistry
  • Cardiology and Cardiovascular Medicine
  • Cell Biology

Cite this

Balyasnikova, Irina V. ; Berestetskaya, Julia V. ; Visintine, David J. ; Nesterovitch, Andrew B. ; Adamian, Larisa ; Danilov, Sergei M. / Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting. In: Microvascular Research. 2010 ; Vol. 80, No. 3. pp. 355-364.
@article{c33d4fa68c924f2fb1c972dba585cd10,
title = "Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting",
abstract = "Monoclonal antibody (mAb) 9B9 to angiotensin-converting enzyme (ACE) demonstrates selective accumulation in lung tissue of the rat, hamster, cat, monkey and human after systemic injection. It has also been demonstrated that mAb 9B9 is the useful tool for targeting therapeutic agents or genes to lung endothelium. In this study, we describe the generation and characterization of a single-chain derivative (scFv) of mAb9B9 (scFv 9B9). In vitro, scFv9B9 retains the ability of the parental antibody to recognize human and rat ACE when expressed both on the surface of phage and as a soluble protein in prokaryotic and eukaryotic expression systems. The ability of scFv 9B9 presented by phage or the soluble protein labeled with I125 to recognize ACE in the pulmonary circulation was also confirmed in an in vivo rat model. Sequence analysis revealed a putative glycosylation site in close proximity to the complementarity determining region 2 (CDR2) of the scFv 9B9 heavy chain. Mutation of Asn68 to Gln in the heavy chain of scFv 9B9 eliminated the glycosylation site and significantly improved the binding affinity of scFv 9B9 to human ACE as determined by cell ELISA and Western Blot. Moreover, Asn68Gln scFv 9B9 showed a greater rate of secretion at 30°C than wild type scFv 9B9, but had a decreased thermal stability at 37°C. The development of a stable and functional single-chain format of mAb 9B9 which specifically recognizes human and rat ACE represents a novel antibody-based reagent suitable for targeted delivery of drugs/genes to the pulmonary circulation.",
keywords = "Angiotensin-converting enzyme, Pulmonary endothelium, Single-chain antibody fragment, Targeting",
author = "Balyasnikova, {Irina V.} and Berestetskaya, {Julia V.} and Visintine, {David J.} and Nesterovitch, {Andrew B.} and Larisa Adamian and Danilov, {Sergei M.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.mvr.2010.09.007",
language = "English (US)",
volume = "80",
pages = "355--364",
journal = "Microvascular Research",
issn = "0026-2862",
publisher = "Academic Press Inc.",
number = "3",

}

Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting. / Balyasnikova, Irina V.; Berestetskaya, Julia V.; Visintine, David J.; Nesterovitch, Andrew B.; Adamian, Larisa; Danilov, Sergei M.

In: Microvascular Research, Vol. 80, No. 3, 01.12.2010, p. 355-364.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting

AU - Balyasnikova, Irina V.

AU - Berestetskaya, Julia V.

AU - Visintine, David J.

AU - Nesterovitch, Andrew B.

AU - Adamian, Larisa

AU - Danilov, Sergei M.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Monoclonal antibody (mAb) 9B9 to angiotensin-converting enzyme (ACE) demonstrates selective accumulation in lung tissue of the rat, hamster, cat, monkey and human after systemic injection. It has also been demonstrated that mAb 9B9 is the useful tool for targeting therapeutic agents or genes to lung endothelium. In this study, we describe the generation and characterization of a single-chain derivative (scFv) of mAb9B9 (scFv 9B9). In vitro, scFv9B9 retains the ability of the parental antibody to recognize human and rat ACE when expressed both on the surface of phage and as a soluble protein in prokaryotic and eukaryotic expression systems. The ability of scFv 9B9 presented by phage or the soluble protein labeled with I125 to recognize ACE in the pulmonary circulation was also confirmed in an in vivo rat model. Sequence analysis revealed a putative glycosylation site in close proximity to the complementarity determining region 2 (CDR2) of the scFv 9B9 heavy chain. Mutation of Asn68 to Gln in the heavy chain of scFv 9B9 eliminated the glycosylation site and significantly improved the binding affinity of scFv 9B9 to human ACE as determined by cell ELISA and Western Blot. Moreover, Asn68Gln scFv 9B9 showed a greater rate of secretion at 30°C than wild type scFv 9B9, but had a decreased thermal stability at 37°C. The development of a stable and functional single-chain format of mAb 9B9 which specifically recognizes human and rat ACE represents a novel antibody-based reagent suitable for targeted delivery of drugs/genes to the pulmonary circulation.

AB - Monoclonal antibody (mAb) 9B9 to angiotensin-converting enzyme (ACE) demonstrates selective accumulation in lung tissue of the rat, hamster, cat, monkey and human after systemic injection. It has also been demonstrated that mAb 9B9 is the useful tool for targeting therapeutic agents or genes to lung endothelium. In this study, we describe the generation and characterization of a single-chain derivative (scFv) of mAb9B9 (scFv 9B9). In vitro, scFv9B9 retains the ability of the parental antibody to recognize human and rat ACE when expressed both on the surface of phage and as a soluble protein in prokaryotic and eukaryotic expression systems. The ability of scFv 9B9 presented by phage or the soluble protein labeled with I125 to recognize ACE in the pulmonary circulation was also confirmed in an in vivo rat model. Sequence analysis revealed a putative glycosylation site in close proximity to the complementarity determining region 2 (CDR2) of the scFv 9B9 heavy chain. Mutation of Asn68 to Gln in the heavy chain of scFv 9B9 eliminated the glycosylation site and significantly improved the binding affinity of scFv 9B9 to human ACE as determined by cell ELISA and Western Blot. Moreover, Asn68Gln scFv 9B9 showed a greater rate of secretion at 30°C than wild type scFv 9B9, but had a decreased thermal stability at 37°C. The development of a stable and functional single-chain format of mAb 9B9 which specifically recognizes human and rat ACE represents a novel antibody-based reagent suitable for targeted delivery of drugs/genes to the pulmonary circulation.

KW - Angiotensin-converting enzyme

KW - Pulmonary endothelium

KW - Single-chain antibody fragment

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=78249246654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249246654&partnerID=8YFLogxK

U2 - 10.1016/j.mvr.2010.09.007

DO - 10.1016/j.mvr.2010.09.007

M3 - Article

VL - 80

SP - 355

EP - 364

JO - Microvascular Research

JF - Microvascular Research

SN - 0026-2862

IS - 3

ER -